Related Experiment Video
Updated: Feb 13, 2026

Determining Genome-wide Transcript Decay Rates in Proliferating and Quiescent Human Fibroblasts
Published on: January 2, 2018
SOX9 Transcriptionally Regulates mTOR-Induced Proliferation of Basal Cell Carcinomas
Arianna L Kim1, Jung Ho Back1, Sandeep C Chaudhary2
1Department of Dermatology, Columbia University Medical Center, New York, New York, USA.
Abstract:
Currently available smoothened targeted therapies in patients with basal cell nevus syndrome are associated with substantial tumor recurrence and clinical resistance. Strategies bypassing smoothened and/or identifying additional downstream components of the Hedgehog pathway could provide novel antitumor targets with a better therapeutic index. Sry-related high mobility group box 9 (SOX9) is a Hedgehog/glioma-associated oncogene homolog-regulated transcription factor known to be overexpressed in basal cell carcinomas (BCCs). A sequence motif search for SOX9-responsive elements identified three motifs in the promoter region of mammalian target of rapamycin (mTOR). In murine BCC cells, SOX9 occupies the mTOR promoter and induces its transcriptional activity. Short hairpin RNA (shRNA)-mediated knockdown of SOX9, as well as smoothened inhibition by itraconazole and vismodegib, reduces mTOR expression and the phosphorylation of known downstream mTOR targets. These effects culminate in diminishing the proliferative capacity of BCC cells, demonstrating a direct mechanistic link between the Hedgehog and mTOR pathways capable of driving BCC growth. Furthermore, rapamycin, a pharmacologic mTOR inhibitor, suppressed the growth of UV-induced BCCs in Ptch1+/-/SKH-1 mice, a model that closely mimics the accelerated BCC growth pattern of patients with basal cell nevus syndrome. Our data demonstrate that Hedgehog signaling converges on mTOR via SOX9, and highlight the SOX9-mTOR axis as a viable additional target downstream of smoothened that could enhance tumor elimination in patients with BCC.
Insights
Targeting the SOX9-mTOR axis offers a new strategy for basal cell carcinoma (BCC) treatment. This pathway bypasses current therapies, potentially improving outcomes for patients with basal cell nevus syndrome.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Current smoothened targeted therapies for basal cell nevus syndrome (BCNS) face challenges with tumor recurrence and resistance.
- Novel therapeutic strategies targeting downstream components of the Hedgehog pathway are needed for improved efficacy and therapeutic index.
Purpose of the Study:
- To investigate the role of Sry-related high mobility group box 9 (SOX9) in basal cell carcinoma (BCC) growth.
- To elucidate the mechanistic link between the Hedgehog and mammalian target of rapamycin (mTOR) pathways in BCC.
- To evaluate the SOX9-mTOR axis as a potential therapeutic target downstream of smoothened.
Main Methods:
- Sequence motif analysis identified SOX9-responsive elements in the mTOR promoter.
- SOX9 knockdown and smoothened inhibition (itraconazole, vismodegib) were performed in murine BCC cells.
- mTOR expression, downstream target phosphorylation, and cellular proliferation were assessed.
- Pharmacologic mTOR inhibition with rapamycin was tested in a UV-induced BCC mouse model (Ptch1+/-/SKH-1).
Main Results:
- SOX9 was found to occupy and induce transcriptional activity of the mTOR promoter in murine BCC cells.
- SOX9 knockdown and smoothened inhibition reduced mTOR expression and downstream signaling, decreasing BCC cell proliferation.
- Rapamycin suppressed UV-induced BCC growth in a mouse model mimicking BCNS.
- Demonstrated a direct mechanistic link between Hedgehog and mTOR pathways driving BCC growth via SOX9.
Conclusions:
- Hedgehog signaling converges on mTOR through SOX9 in BCC.
- The SOX9-mTOR axis represents a viable therapeutic target downstream of smoothened.
- Targeting this axis could enhance tumor elimination in patients with BCC and BCNS.
Related Concept Videos
Master Transcription Regulators
Master Transcription Regulators
Cooperative Binding of Transcription Regulators
Cooperative Binding of Transcription Regulators
Transcriptional Regulation: Riboswitches
Transcription Factors

